Can a common heart drug prevent bleeding in cirrhosis?
NCT ID NCT06861075
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether carvedilol, a beta-blocker, can reduce high blood pressure in the liver's portal vein in people with cirrhosis. High pressure can lead to dangerous bleeding. Researchers will use an endoscopic ultrasound to measure pressure before and after one month of treatment. The trial enrolls 30 adults with cirrhosis and suspected portal hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carvedilol (a beta-blocker drug)
What this could lead to
If it works, this could provide a simple way to measure and reduce bleeding risk in people with cirrhosis.
What could go wrong
This is a small, early-phase study with only 30 people. The drug may not lower pressure enough, and side effects like dizziness or fatigue are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Estaing Medecine Digestive Et Hepatobiliaire
RECRUITINGClermont-Ferrand, 63003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lise Laclautre
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact